Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
HL-A antigens and multiple sclerosis.
Decreased microglial activation in MS patients treated with glatiramer acetate.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
Ofatumumab Dose-finding in RRMS Patients
Colestipol May Quickly Eliminate Teriflunomide
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
A genome-wide association study of brain lesion distribution in multiple sclerosis.
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Laquinimod Phase IIa Study in Active Crohn's Disease

Pages